ES2178808T3 - Derivados omega-cicloalquil-prostaglandina e2. - Google Patents

Derivados omega-cicloalquil-prostaglandina e2.

Info

Publication number
ES2178808T3
ES2178808T3 ES98300769T ES98300769T ES2178808T3 ES 2178808 T3 ES2178808 T3 ES 2178808T3 ES 98300769 T ES98300769 T ES 98300769T ES 98300769 T ES98300769 T ES 98300769T ES 2178808 T3 ES2178808 T3 ES 2178808T3
Authority
ES
Spain
Prior art keywords
rent
group
halogen atom
same
prostaglandina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98300769T
Other languages
English (en)
Inventor
Kousuke Tani
Shuichi Ohuchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2178808T3 publication Critical patent/ES2178808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS OE -CICLOALQUILO DE LA PROSTAGLANDINA E 2 DE FORMULA (I): DONDE R ES UN GRUPO CARBOXI O HIDROMETILO; R SUP,1 ES UN GRUPO OXO, METILENO O UN ATOMO HALOGENO; R 2 ES H, OH O UN GRUPO C1-4 ALQUIOXILO; R 3 ES H, UN GRUPO C1-8 ALQUILO, C2-8 ALQUENILO, C2-8 ALQUINILO, C1-8 ALQUILO, C2-8 ALQUENILO O C2-8 ALQUINILO SUSTITUIDO POR 1.3 SUSTITUYENTES SELECCIONADOS ENTRE UN ATOMO HALOGENO, UN GRUPO C1-4 ALQUIOXILO, C3-7 CICLOALQUILO, FENILO, Y FENILO SUSTITUIDO POR 1-3 SUSTITUYENTES SELECCIONADOS ENTRE UN ATOMO HALOGENO, UN GRUPO C1-4 ALQUILO, C1-4 ALQUIOXILO, NITRO Y TRIFLUOROMETILO; N ES 0-4; Y SALES NO TOXICAS DE LOS MISMOS, PROFARMACOS DE LOS MISMOS Y CICLODEXTRINAS CLATRATOS DE LOS MISMOS UNIDOS FUERTEMENTE AL SUBTIPO EP 2 DEL RECEPTOR. POR TANTO, SON UTILES PARA LA PRE VENCION Y/O EL TRATAMIENTO DE ENFERMEDADES INMUNOLOGICAS (ENFERMEDADES AUTOINMUNES, TRASPLANTE DE ORGANOS, ETC.), ASMA, FORMACION ANORMAL DE HUESOS, MUERTE NEURONAL, LESION HEPATICA, ABORTO, NACIMIENTO PREMATURO O RETINOPATIA GLAUCOMATOSA, ETC.
ES98300769T 1997-02-04 1998-02-03 Derivados omega-cicloalquil-prostaglandina e2. Expired - Lifetime ES2178808T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3549997 1997-02-04
JP31916997 1997-11-06

Publications (1)

Publication Number Publication Date
ES2178808T3 true ES2178808T3 (es) 2003-01-01

Family

ID=26374500

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98300769T Expired - Lifetime ES2178808T3 (es) 1997-02-04 1998-02-03 Derivados omega-cicloalquil-prostaglandina e2.

Country Status (13)

Country Link
US (3) US6110969A (es)
EP (1) EP0860430B1 (es)
KR (1) KR100573535B1 (es)
AT (1) ATE219054T1 (es)
AU (1) AU736271B2 (es)
CA (1) CA2228828A1 (es)
DE (1) DE69805874T2 (es)
DK (1) DK0860430T3 (es)
ES (1) ES2178808T3 (es)
HU (1) HUP9800208A3 (es)
NO (1) NO317155B1 (es)
PT (1) PT860430E (es)
TW (1) TW581756B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2303341T3 (es) 1996-12-20 2008-08-01 Pfizer Inc. Prevencion y tratamiento de trastorno del esqueleto con agonistas de la prostaglandina e2 selectivos del subtipo de receptor ep2.
US6235780B1 (en) * 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
KR20030019628A (ko) * 2000-07-31 2003-03-06 오노 야꾸힝 고교 가부시키가이샤 프로스타글란딘 유도체를 유효 성분으로 하는 발기부전치료제
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
JP3678366B2 (ja) 2002-08-09 2005-08-03 大正製薬株式会社 止痒剤
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
AU2003301900A1 (en) * 2002-11-13 2004-06-03 Fumie Sato Antipruritic drug
WO2004073591A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
US20070167403A1 (en) * 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
EP2422814A1 (en) 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
JP4893999B2 (ja) * 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
RU2420316C2 (ru) 2005-06-03 2011-06-10 Оно Фармасьютикал Ко., Лтд. Агент для регенерации и/или защиты нервов
US7563924B2 (en) * 2005-11-21 2009-07-21 Schering Aktiengesellschaft 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
LT1976828T (lt) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
EP2269611B1 (en) 2006-11-16 2016-03-23 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
JO3032B1 (ar) * 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
TW201311630A (zh) 2011-08-05 2013-03-16 Ono Pharmaceutical Co 軟骨疾病治療用化合物
BR112014003802A2 (pt) * 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
RU2474426C1 (ru) * 2011-12-26 2013-02-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Простамиды и их аналоги, обладающие нейрозащитным действием
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
EP2913047B1 (en) 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
EP2818484A1 (en) 2013-06-28 2014-12-31 Universitat Autònoma de Barcelona Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
US10385007B2 (en) 2016-12-09 2019-08-20 Celtaxsys, Inc. Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase
AU2017371348B2 (en) 2016-12-09 2022-02-03 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
US10202334B2 (en) 2016-12-09 2019-02-12 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061670A (en) * 1976-07-19 1977-12-06 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic acids and congeners
US4132738A (en) * 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
US4336404A (en) * 1979-05-14 1982-06-22 Miles Laboratories, Inc. 1-Acyloxy-15-deoxy-16-hydroxy-analogs of prostaglandin E1
US4363817A (en) * 1981-08-27 1982-12-14 Miles Laboratories, Inc. Enol acylate analogs of E1 and E2 prostaglandins
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
NO980442L (no) 1998-08-05
HUP9800208A3 (en) 2000-04-28
NO980442D0 (no) 1998-02-02
PT860430E (pt) 2002-11-29
EP0860430B1 (en) 2002-06-12
AU5289298A (en) 1998-08-06
AU736271B2 (en) 2001-07-26
US6110969A (en) 2000-08-29
EP0860430A2 (en) 1998-08-26
HU9800208D0 (en) 1998-03-30
KR100573535B1 (ko) 2006-12-15
EP0860430A3 (en) 1999-06-23
US20030186939A1 (en) 2003-10-02
TW581756B (en) 2004-04-01
DE69805874T2 (de) 2002-12-19
US6576785B1 (en) 2003-06-10
NO317155B1 (no) 2004-08-30
DE69805874D1 (de) 2002-07-18
ATE219054T1 (de) 2002-06-15
DK0860430T3 (da) 2002-09-09
KR19980071021A (ko) 1998-10-26
CA2228828A1 (en) 1998-08-04
HUP9800208A2 (hu) 1998-09-28

Similar Documents

Publication Publication Date Title
ES2178808T3 (es) Derivados omega-cicloalquil-prostaglandina e2.
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ES2182220T3 (es) Derivados de acido 3,7-ditiaprostanoico.
CR20120007A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
ES2168487T3 (es) Derivados de n-heteroaril-piridinasulfonamida y su uso como antagonistas de la endotelina.
ES2266459T3 (es) Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia.
BR9811585A (pt) Agonistas de vasopressinas tricìclicas
BR9811774A (pt) Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
ES2178352T3 (es) Derivados de omega-cicloaquil-prostaglandina e1.
ES2137991T3 (es) Eniantinas y derivados de eniantina para la lucha contra los endoparasitos.
ES2190458T3 (es) Empleo de dioxomorfolinas para la lucha contra los endoparasitos, nuevas dioxomorfolinas y procedimientos para su obtencion.
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
ES2152444T3 (es) Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos.
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
AR035739A1 (es) Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
PE44597A1 (es) Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
AR002690A1 (es) Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado.
AR007135A1 (es) Compuestos de benzofurano y benzopirano, formulaciones farmaceuticas que los contienen y metodos para preparar los compuestos y las formulaciones
AR004158A1 (es) Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto.
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
MX9305256A (es) Derivados de 7-isoindolinil-quinolona y derivados de7-isoindolinil-naftiridona, proceso para su preparacion y medicamentos quelos contienen.
ES2191180T3 (es) Antagonistas de los receptores de la dopamina benzoxazinona d4.
ES2090081T3 (es) Derivados de indolocarbazol, procedimientos para su obtencion y su empleo.